Deal overview
| Target | ZEALAND PHARMA A/S (PETRELINTIDE RIGHTS) |
|---|---|
| Bidder | ROCHE HOLDING AG |
| Price | £50.00 Full version or £25.00 Light version |
| Publication Date | Mar 12, 2025 |
| Abstract | On 12 March 2025, the quoted Swiss healthcare company Roche Holdings AG ("Roche") announced that it had entered into an exclusive collaboration and licensing agreement with the Danish-based biotechnology company Zealand Pharma A/S ("Zealand Pharma") to co-develop and co-commercialise petrelintide, Zealand Pharma's amylin analog as a standalone therapy as well as a fixed-dose ... |
| Number of pages (Full version) | 5 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
